The European Association of Urology (EAU) [14,15] and National Comprehensive Cancer Network (NCCN) [16] guidelines recommend the use of PSMA-PET for lesion evaluation in biochemical recurrence patients, staging of high-risk localized prostate cancer, and expression evaluation in metastatic prostate cancer before PSMA-RLT. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.